---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-028194"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:24:59.183263+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore converts TEBE-AM to registrational Phase 3 evaluating KIMMTRAK for cutaneous melanoma

## Summary
- Trial converted to Phase 3 registrational after FDA consultation; three arms: KIMMTRAK monotherapy, KIMMTRAK+pembrolizumab, control.
- All patients randomized from trial start included in Phase 3 intent-to-treat population; time to final OS analysis expected to accelerate.
- Phase 3 to test KIMMTRAK in previously treated advanced cutaneous melanoma; rapid accrual made Phase 2 OS maturity timeline moot.
- Phase 1b data showed ~75% one-year OS rate for KIMMTRAK+checkpoint combo in metastatic cutaneous melanoma patients.

## SEC filing metadata
- accession: 0001140361-24-028194
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124028194/0001140361-24-028194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124028194/ef20030315_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-028194
- JSON: https://secwatch.observer/filing/0001140361-24-028194.json
- Plain text: https://secwatch.observer/filing/0001140361-24-028194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.